Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
62
LMAT Quote, Financials, Valuation and Earnings
Last price:
$107.46
Seasonality move
:
3.92%
Day range:
$101.92 - $115.33
52-week range:
$71.42 - $115.33
Dividend yield:
0.7%
P/E ratio:
45.20x
P/S ratio:
10.61x
P/B ratio:
6.81x
Volume:
1.3M
Avg. volume:
178.4K
1-year change:
10.33%
Market cap:
$2.6B
Revenue:
$249.6M
EPS (TTM):
$2.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
$62.8M | $0.66 | 11.25% | 36.65% | $107.00 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
ARAY
Accuray, Inc.
|
$100.9M | -$0.11 | -1.19% | -296.83% | $2.53 |
|
OSUR
OraSure Technologies, Inc.
|
$26.4M | -$0.15 | -7.72% | -34.16% | $6.00 |
|
PRCT
PROCEPT BioRobotics Corp.
|
$93.7M | -$0.32 | 17.43% | -20.73% | $39.60 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
$113.69 | $107.00 | $2.6B | 45.20x | $0.20 | 0.7% | 10.61x |
|
ABT
Abbott Laboratories
|
$116.26 | $133.39 | $202.2B | 31.28x | $0.63 | 2.06% | 4.59x |
|
ARAY
Accuray, Inc.
|
$0.58 | $2.53 | $69.5M | 149.00x | $0.00 | 0% | 0.15x |
|
OSUR
OraSure Technologies, Inc.
|
$3.08 | $6.00 | $220.9M | 26.67x | $0.00 | 0% | 1.97x |
|
PRCT
PROCEPT BioRobotics Corp.
|
$23.63 | $39.60 | $1.3B | -- | $0.00 | 0% | 4.26x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.32 | $5.50 | $44.6M | -- | $0.00 | 0% | 5.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
32.05% | 0.111 | 10.09% | 10.81x |
|
ABT
Abbott Laboratories
|
21.33% | 0.141 | 6.97% | 1.05x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.394 | 177.87% | 0.52x |
|
OSUR
OraSure Technologies, Inc.
|
-- | 0.712 | -- | 5.57x |
|
PRCT
PROCEPT BioRobotics Corp.
|
17.66% | 0.862 | 4.46% | 5.62x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
$46.2M | $18.8M | 10.5% | 15.86% | 29.22% | $26.5M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
OSUR
OraSure Technologies, Inc.
|
$11M | -$16.9M | -17.66% | -18.18% | -62.97% | -$9.9M |
|
PRCT
PROCEPT BioRobotics Corp.
|
$46.3M | -$31M | -20.6% | -24.85% | -40.64% | -$9.5M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
LeMaitre Vascular, Inc. vs. Competitors
-
Which has Higher Returns LMAT or ABT?
Abbott Laboratories has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of 15.71%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About LMAT or ABT?
LeMaitre Vascular, Inc. has a consensus price target of $107.00, signalling downside risk potential of -5.88%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 14.73%. Given that Abbott Laboratories has higher upside potential than LeMaitre Vascular, Inc., analysts believe Abbott Laboratories is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 5 0 ABTAbbott Laboratories16 7 0 -
Is LMAT or ABT More Risky?
LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock LMAT or ABT?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.7%. Abbott Laboratories offers a yield of 2.06% to investors and pays a quarterly dividend of $0.63 per share. LeMaitre Vascular, Inc. pays 31.75% of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or ABT?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. LeMaitre Vascular, Inc.'s net income of $15.6M is lower than Abbott Laboratories's net income of $1.8B. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 45.20x while Abbott Laboratories's PE ratio is 31.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.61x versus 4.59x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.61x 45.20x $64.5M $15.6M ABTAbbott Laboratories4.59x 31.28x $11.5B $1.8B
-
Which has Higher Returns LMAT or ARAY?
Accuray, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -13.47%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About LMAT or ARAY?
LeMaitre Vascular, Inc. has a consensus price target of $107.00, signalling downside risk potential of -5.88%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 331.7%. Given that Accuray, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Accuray, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 5 0 ARAYAccuray, Inc.2 0 0 -
Is LMAT or ARAY More Risky?
LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.
-
Which is a Better Dividend Stock LMAT or ARAY?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.7%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.75% of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or ARAY?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 45.20x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.61x versus 0.15x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.61x 45.20x $64.5M $15.6M ARAYAccuray, Inc.0.15x 149.00x $102.2M -$13.8M
-
Which has Higher Returns LMAT or OSUR?
OraSure Technologies, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -72.06%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat OraSure Technologies, Inc.'s return on equity of -18.18%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M OSUROraSure Technologies, Inc.40.98% -$0.27 $340.8M -
What do Analysts Say About LMAT or OSUR?
LeMaitre Vascular, Inc. has a consensus price target of $107.00, signalling downside risk potential of -5.88%. On the other hand OraSure Technologies, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 94.81%. Given that OraSure Technologies, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe OraSure Technologies, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 5 0 OSUROraSure Technologies, Inc.1 2 0 -
Is LMAT or OSUR More Risky?
LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison OraSure Technologies, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.058%.
-
Which is a Better Dividend Stock LMAT or OSUR?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.7%. OraSure Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.75% of its earnings as a dividend. OraSure Technologies, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or OSUR?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are larger than OraSure Technologies, Inc. quarterly revenues of $26.8M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than OraSure Technologies, Inc.'s net income of -$19.3M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 45.20x while OraSure Technologies, Inc.'s PE ratio is 26.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.61x versus 1.97x for OraSure Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.61x 45.20x $64.5M $15.6M OSUROraSure Technologies, Inc.1.97x 26.67x $26.8M -$19.3M
-
Which has Higher Returns LMAT or PRCT?
PROCEPT BioRobotics Corp. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -39.07%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat PROCEPT BioRobotics Corp.'s return on equity of -24.85%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M PRCTPROCEPT BioRobotics Corp.60.63% -$0.53 $444.4M -
What do Analysts Say About LMAT or PRCT?
LeMaitre Vascular, Inc. has a consensus price target of $107.00, signalling downside risk potential of -5.88%. On the other hand PROCEPT BioRobotics Corp. has an analysts' consensus of $39.60 which suggests that it could grow by 67.58%. Given that PROCEPT BioRobotics Corp. has higher upside potential than LeMaitre Vascular, Inc., analysts believe PROCEPT BioRobotics Corp. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 5 0 PRCTPROCEPT BioRobotics Corp.7 2 0 -
Is LMAT or PRCT More Risky?
LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison PROCEPT BioRobotics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LMAT or PRCT?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.7%. PROCEPT BioRobotics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.75% of its earnings as a dividend. PROCEPT BioRobotics Corp. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or PRCT?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are smaller than PROCEPT BioRobotics Corp. quarterly revenues of $76.4M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than PROCEPT BioRobotics Corp.'s net income of -$29.8M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 45.20x while PROCEPT BioRobotics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.61x versus 4.26x for PROCEPT BioRobotics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.61x 45.20x $64.5M $15.6M PRCTPROCEPT BioRobotics Corp.4.26x -- $76.4M -$29.8M
-
Which has Higher Returns LMAT or PSTV?
Plus Therapeutics, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -316.61%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About LMAT or PSTV?
LeMaitre Vascular, Inc. has a consensus price target of $107.00, signalling downside risk potential of -5.88%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1595.96%. Given that Plus Therapeutics, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 5 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is LMAT or PSTV More Risky?
LeMaitre Vascular, Inc. has a beta of 0.719, which suggesting that the stock is 28.103% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock LMAT or PSTV?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.7%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.75% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or PSTV?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 45.20x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.61x versus 5.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.61x 45.20x $64.5M $15.6M PSTVPlus Therapeutics, Inc.5.20x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 15.34% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.22% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.48% over the past day.
